A recent study found that rimegepant, an orally administered calcitonin gene-related peptide receptor antagonist, is safe and well-tolerated for up to 52 weeks in individuals with migraine, with no signs of...
In this “Test Your Knowledge” series, Edward Shahady, MD, asks you to choose the most appropriate treatment approach for a middle-aged Black man with prediabetes.